Utang jangka cendhak perusahaan: MacroGenics, Inc. (MGNX)

Risks for MacroGenics, Inc. (MGNX) are linked to the high cost of developing DART bispecific molecules. The current liability metric visualizes these expenses, where 0.03 represents the current level of the metric. Payments for Margenza and partnerships with pharma behemoths provide stability. A safe liquidity buffer and the success of clinical trials for targeted drugs minimize threats associated with therapy side effects.

Investors are assessing the issuer's margin of safety through the volume of liabilities maturing within one year, which determines the business's ability to service debt without sacrificing liquidity. For MacroGenics, Inc. (MGNX), whose revenue depends on the commercialization of oncology drugs and partner payments, an analysis of current loans and borrowings reveals whether debt payments are restricting R&D investments, thereby determining the asset's reliability class.